Nanoparticulate drug delivery systems for the treatment of diabetes

Digest Journal of Nanomaterials and Biostructures

Volumn 5, Issue 2, 2010, Pages 414-418

  Sona, P S ^a  

^a Parul Institute of Pharmacy and Research   (India)

Author keywords

Blood glucose level; Diabetes; Insulin; Nano particle drug delivery

Indexed keywords

EID: 77955343894     PISSN: None     EISSN: 18423582     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Kuzuya T, Nakagawa S, Satoh J, et al. Diabetes Res Clin Pract 55(1),65-85 (2002).
2. Attivi D, Wehrle P, Ubrich N, et al. Drug Dev Ind Pharm 31(2),179-189 (2005).
3. Kost J, Horbett TA, Ratner BD, et al. J Biomed Mater Res, 19, 1117-1133(1985).
4. Ishihara K, Kobayashi M, Shinohara I. Makromol Chem Rapid Commun, 4,327(1983)
5. Dorski CM, Doyle FJ, Peppas NA. Polym Mater Sci Eng Proc, 76,281-282 (1997).
6. Morishita M, Morishita I, Takayama K, et al. Int J Pharm, 78(1-3), 1-7 (1992).
7. Morcol T, Nagappan P, Nerenbaum L, et al. Int J Pharm, 277(1-2),91-97 (2004).
8. Venugopalan P, Sapre A, Venkatesan N, et al. Pharmazie, 56(3), 217-219 (2001).
9. Leobandung W, Ichikawa H, Fukumori Y, et al. J Control release, 80(1-3), 357-363 (2002).
10. Pan Y, Li YJ, Zhao HY, et al. Int J Pharm, 249(1-2):139-147 (2002).
11. Lin YH, Mi FL, Chen CT, et al. Biomacromolecules, 8(1)146-152, (2007).
12. Sarmento B, Ribeiro A, Veiga F, et al. Colloids Surf B Biointerfaces,53(2),193 (2006).
13. Tiyaboonchai W, Woiszwillo J, Sims RC, et al. Int J Pharm, 255(1-2), 139-151 (2003).
14. Sajeesh S, Sharma CP. Int J Pharm. 325(1-2):147-154 (2006).
15. Mesiha MS, Sidhom MB, Fasipe B. Int J Pharm 288(2):289-293 (2005).
16. Cui FD, Tao AJ, Cun DM, et al. J Pharm Sci 96(2),421-427 (2007)
17. Damg'e C, Maincent P, Ubrich N. J Control Release, 117(2),163-170 (2007)
18. Xiong XY, Li YP, Li ZL, et al. J Control Release, 120(1-2), 11-17 (2007).
19. Liu J, Zhang SM, Chen PP, et al. J Mater Sci Mater Med, 18(11), 2205-2210 (2007).
20. Sarmento B, Ribeiro A, Veiga F, et al. Pharm Res, 24(12), 2198-2206 (2007).
21. Pandey R, Sharma A, Zahoor A, et al. J Antimicrob Chemother, 52(6),981-986 (2003).
22. Cherian AK, Rana AC, Jain SK. Drug Dev Ind Pharm, 26(4),459-463 (2000).
23. Corkery K. Inhalable drugs for systemic therapy. Respir Care, 45(7), 831-835 (2000).
24. Paul W, Sharma C. Trends Biomed Artif Organs, 14(2), 37-38 (2001).
25. Kawashima Y, Yamamoto H, Takeuchi H, et al. J Control Release, 62(1-2), 279-287(1999).
26. Zhang Q, Shen Z, Nagai T. Int J Pharm,218 (1-2),75-80 (2001).
27. O'Hagan DT, Illum L. Crit Rev Ther Drug Carrier Syst, 7(1), 35-97(1990).
28. Grenha A, Seijo B, Remũnan-Ĺopez C. Eur J Pharm Sci 25(4-5), 427-437(2005).
29. Jain AK, Khar RK, Ahmed FJ, et al. Eur J Pharm Biopharm, 69(2), 426-435(2008).
30. Maillefer D, Gamper S, Frehner B, et al. 14th IEEE Int Conf MEMS Tech Digest, 413-417.
31. Leadership Medica. Biomedical technology. Available at: http://www.leadershipmedica.com/scientifico/sciesett02/scientificaing/7ferrarie/7ferraring.htm. Accessed September(2008).
32. Ziaie B, Baldi A, Lei M, et al. Adv Drug Deliv Rev, 56(2), 145-172(2004).
33. Wong E, Bigdeli A, Biglari-Abhari M. A conducting polymer-based self-regulating Insulin delivery system. Int J Sci Res,16, 235 (2006).
34. Martanto W, Davis SP, Holiday NR, et al. Transdermal delivery of insulin using microneedles in vivo. Pharm Res, 21(6),947-952 (2004).
35. Desai TA, Hansford D, Ferrari M. Characterization of micromachined silicon membranes for immunoisolation and bioseparation applications. J Membr Sci, 159(1-2),221-231(1999).
36. Tao SL, Desai TA. Microfabricated drug delivery systems: From particles to pores. Adv Drug Deliv Rev, 55,315-328 (2003).
37. Bhumkar DR, Joshi HM, Sastry M, et al. Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin. Pharm Res, 24(8),1415-1426(2007).
38. Chalasani KB, Russell-Jones GJ, Yandrapu SK, et al. A novel vitamin B12-nanosphere Conjugate carrier system for peroral delivery of insulin. J Control Release, 117(3),421-429(2007).
39. Zimmer A, Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev, 16(1),61-739(1995).
40. Gurny R, Boye T, Ibrahim H. Ocular therapy with nanoparticulate systems for controlled drug delivery. J Control Release, 2,353-361(1985).
41. De TK, Rodman DJ, Holm BA, et al. Brimonidine formulation in polyacrylic acid nanoparticles for ophthalmic delivery. J Microencapsul, 20(3), 361-374 (2003)
42. Bourges JL, Gautier SE, Delie F, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci, 44(8), 3562-3569 (2003).
43. Enri ́quez de Salamanca A, Diebold Y, Calonge M, et al. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: Toxicity, uptake mechanism and in vivotolerance. Invest Ophthalmol Vis Sci, 47(4), 1416-1425 (2006).
44. Neuberger T, Schopf B, Hofmann H, et al. Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. J Magn Magn Mater, 293(1), 483-496(2005).
45. Kayser O, Lemker A, Trejo NH. The impact of nanobiotechnology on the development of new drug delivery systems. Curr Pharm Biotechnol, 6, 3-5 (2005).
46. Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after Intravenous administration: Effect of particle size. Colloids Surf B Biointerfaces, 66(2), 274-280 (2008).